SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Miller who wrote (3254)6/8/1999 11:13:00 AM
From: BMcV  Read Replies (2) of 10280
 
That was my first thought, too, Don.

>>UCB will pay Sepracor royalties five percent on sales of the drug, levocetirizne, which is part of the same family of drugs as Zyrtec. "That's peanuts," Jacobs said<<

I've been waiting for someone to weigh in with a measured response to this (sounds like it hurts, doesn't it?), but since no one has:

OUCH! Stop it! You're hurting me!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News